Treatment-Resistant Depression Market Report 2026
Download Free Sample Buy Now
Treatment-Resistant Depression Market Global Report 2026 Market Report Infographic Image

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Treatment-Resistant Depression Market Report 2026

Global Outlook – By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Psychedelics), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Homecare, Specialty Clinics, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Treatment-Resistant Depression Market Overview

• Treatment-Resistant Depression market size has reached to $1.87 billion in 2025

• Expected to grow to $2.59 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%

• Growth Driver: High Prevalence Of Mental Disorders Driving The Market Due To Increasing Incidence Of Treatment Non-Response

• Market Trend: Innovative Therapies To Address Unmet Patient Needs In Treatment-Resistant Depression

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Treatment-Resistant Depression Market?

Treatment-resistant depression (TRD) is a severe and persistent form of major depressive disorder (MDD) characterized by inadequate response to at least two different antidepressant treatments of adequate dose and duration, leading to prolonged psychological distress and functional impairment. Individuals with TRD often require advanced therapeutic approaches, including novel pharmacological treatments, neuromodulation techniques, and personalized mental health interventions, to achieve symptom relief and improve overall well-being.

The main drug classes in treatment-resistant depression are selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, tricyclic antidepressant, psychedelics, and others. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant medications that function by increasing serotonin levels in the brain by inhibiting its reabsorption into neurons, thereby enhancing mood regulation and treating conditions such as depression and anxiety disorders. The drugs are administered through routes including oral, parenteral, and others, which are distributed by various channels such as hospital pharmacies, retail pharmacies, and online pharmacies for the end users, including hospitals, homecare, specialty clinics, and others.

Treatment-Resistant Depression Market Global Report 2026 Market Report bar graph

What Is The Treatment-Resistant Depression Market Size and Share 2026?

The treatment-resistant depression market size has grown strongly in recent years. It will grow from $1.87 billion in 2025 to $2 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to rising prevalence of major depressive disorder, limited efficacy of conventional antidepressants, increased diagnosis of refractory depression cases, expansion of psychiatric specialty clinics, growing acceptance of advanced mental health therapies.

What Is The Treatment-Resistant Depression Market Growth Forecast?

The treatment-resistant depression market size is expected to see strong growth in the next few years. It will grow to $2.59 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing investments in precision psychiatry, growing approval of ketamine and esketamine therapies, expansion of biomarker-driven treatment selection, rising demand for long-term depression management solutions, increased use of digital therapeutic support tools. Major trends in the forecast period include increasing adoption of novel rapid-acting antidepressants, rising use of neuromodulation therapies, growing focus on personalized psychiatry approaches, expansion of psychedelic-based treatment research, enhanced integration of digital mental health tools.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Treatment-Resistant Depression Market Segmentation

1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIs), Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Psychedelics

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram

2) By Monoamine Oxidase Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline

3) By Tricyclic Antidepressants (TCAs): Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Doxepin

4) By Psychedelics: Ketamine, Esketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA)

What Is The Driver Of The Treatment-Resistant Depression Market?

The high prevalence of mental disorders is expected to propel the growth of the treatment-resistant depression market going forward. Mental disorders are a broad range of conditions that affect an individual’s cognitive, emotional, and behavioral functioning, often leading to significant distress and impairment in daily life. The high prevalence of mental disorders is driven by factors such as genetic predisposition, as inherited genetic variations can influence brain chemistry and increase susceptibility to conditions such as depression, anxiety, and schizophrenia. Treatment-resistant depression (TRD) supports mental disorder patients by encouraging the use of more personalized and advanced treatments when standard therapies don’t work, helping improve their chances of recovery and quality of life. For instance, in November 2023, according to the American Psychological Association (APA), a US-based scientific and professional organization, among adults, those aged 18 to 34 reported the highest rate of mental illnesses at 50% in 2023, while adults aged 35 to 44 experienced the largest increase in diagnoses, with 45% reporting a mental illness. Therefore, the high prevalence of mental disorders is driving the growth of the treatment-resistant depression industry.

Key Players In The Global Treatment-Resistant Depression Market

Major companies operating in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience

Global Treatment-Resistant Depression Market Trends and Insights

Major companies operating in the treatment-resistant depression market are focusing on developing innovative therapies such as monotherapy to address unmet patient needs, improve efficacy, and reduce side effects. Monotherapy is the use of a single treatment or medication to treat a condition, rather than combining it with others. It helps to treat treatment-resistant depression by offering a single, focused treatment that may be more effective for patients who haven't responded to multiple medications. For instance, in January 2025, Johnson & Johnson Services Inc., a US-based pharmaceutical, biotechnology, and medical technology company, announced U.S. Food and Drug Administration (FDA), a US-based government regulatory body, approval for SPRAVATO (esketamine) nasal spray, a fast-acting treatment for adults with treatment-resistant depression (TRD). SPRAVATO is used alongside an oral antidepressant when patients have not responded adequately to at least two other antidepressant therapies. The drug's rapid effects address the limitations of traditional antidepressants, which often take weeks to show results. As a derivative of ketamine, esketamine works by targeting the brain's NMDA receptors, potentially improving mood within hours. The approval marked a significant advancement in the field of mental health treatment.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Treatment-Resistant Depression Market?

In October 2024, Resilience Lab, a US-based health care company, acquired Options MD for an undisclosed amount. With this acquisition, Resilience Lab aims to strengthen its mental health service offerings by integrating Options MD’s specialized treatment platform for severe and treatment-resistant depression, thereby expanding access to personalized and evidence-based care. Options MD is a US-based telepsychiatry company treating severe and treatment-resistant depression (TRD), bipolar disorder, post-traumatic stress disorder (PTSD), and other mental health conditions.

Regional Outlook

North America was the largest region in the treatment-resistant depression market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Treatment-Resistant Depression Market?

The treatment-resistant depression market consists of revenues earned by entities by providing services such as psychiatric counseling, cognitive behavioral therapy (CBT), transcranial magnetic stimulation (TMS) therapy, electroconvulsive therapy (ECT), and ketamine infusion therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The treatment-resistant depression market includes sales of products such as esketamine nasal spray, vagus nerve stimulation (VNS) devices, deep brain stimulation (DBS) systems, neuromodulation devices, glutamate receptor modulators, and digital therapeutics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Treatment-Resistant Depression Market Report 2026?

The treatment-resistant depression market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the treatment-resistant depression industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Treatment-Resistant Depression Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $2 billion
Revenue Forecast In 2035 $2.59 billion
Growth Rate CAGR of 6.9% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Drug Class, Route Of Administration, Distribution Channel, End-User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Pfizer Inc., Johnson & Johnson Services Inc., Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Treatment-Resistant Depression Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Treatment-Resistant Depression Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Treatment-Resistant Depression Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Treatment-Resistant Depression Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.1.5 Industry 4.0 & Intelligent Manufacturing

4.2. Major Trends

4.2.1 Increasing Adoption Of Novel Rapid-Acting Antidepressants

4.2.2 Rising Use Of Neuromodulation Therapies

4.2.3 Growing Focus On Personalized Psychiatry Approaches

4.2.4 Expansion Of Psychedelic-Based Treatment Research

4.2.5 Enhanced Integration Of Digital Mental Health Tools

5. Treatment-Resistant Depression Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Mental Health Centers

5.4 Homecare Settings

5.5 Rehabilitation Centers

6. Treatment-Resistant Depression Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Treatment-Resistant Depression Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Treatment-Resistant Depression PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Treatment-Resistant Depression Market Size, Comparisons And Growth Rate Analysis

7.3. Global Treatment-Resistant Depression Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Treatment-Resistant Depression Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Treatment-Resistant Depression Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Treatment-Resistant Depression Market Segmentation

9.1. Global Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Selective Serotonin Reuptake Inhibitors (SSRIs), Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Psychedelics

9.2. Global Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Parenteral, Other Routes Of Administration

9.3. Global Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

9.4. Global Treatment-Resistant Depression Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Homecare, Specialty Clinics, Other End-Users

9.5. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Selective Serotonin Reuptake Inhibitors (SSRIs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram

9.6. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Monoamine Oxidase Inhibitors (MAOIs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline

9.7. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Tricyclic Antidepressants (TCAs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Doxepin

9.8. Global Treatment-Resistant Depression Market, Sub-Segmentation Of Psychedelics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Ketamine, Esketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA)

10. Treatment-Resistant Depression Market Regional And Country Analysis

10.1. Global Treatment-Resistant Depression Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Treatment-Resistant Depression Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Treatment-Resistant Depression Market

11.1. Asia-Pacific Treatment-Resistant Depression Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Treatment-Resistant Depression Market

12.1. China Treatment-Resistant Depression Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Treatment-Resistant Depression Market

13.1. India Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Treatment-Resistant Depression Market

14.1. Japan Treatment-Resistant Depression Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Treatment-Resistant Depression Market

15.1. Australia Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Treatment-Resistant Depression Market

16.1. Indonesia Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Treatment-Resistant Depression Market

17.1. South Korea Treatment-Resistant Depression Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Treatment-Resistant Depression Market

18.1. Taiwan Treatment-Resistant Depression Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Treatment-Resistant Depression Market

19.1. South East Asia Treatment-Resistant Depression Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Treatment-Resistant Depression Market

20.1. Western Europe Treatment-Resistant Depression Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Treatment-Resistant Depression Market

21.1. UK Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Treatment-Resistant Depression Market

22.1. Germany Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Treatment-Resistant Depression Market

23.1. France Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Treatment-Resistant Depression Market

24.1. Italy Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Treatment-Resistant Depression Market

25.1. Spain Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Treatment-Resistant Depression Market

26.1. Eastern Europe Treatment-Resistant Depression Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Treatment-Resistant Depression Market

27.1. Russia Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Treatment-Resistant Depression Market

28.1. North America Treatment-Resistant Depression Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Treatment-Resistant Depression Market

29.1. USA Treatment-Resistant Depression Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Treatment-Resistant Depression Market

30.1. Canada Treatment-Resistant Depression Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Treatment-Resistant Depression Market

31.1. South America Treatment-Resistant Depression Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Treatment-Resistant Depression Market

32.1. Brazil Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Treatment-Resistant Depression Market

33.1. Middle East Treatment-Resistant Depression Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Treatment-Resistant Depression Market

34.1. Africa Treatment-Resistant Depression Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Treatment-Resistant Depression Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Treatment-Resistant Depression Market Regulatory and Investment Landscape

36. Treatment-Resistant Depression Market Competitive Landscape And Company Profiles

36.1. Treatment-Resistant Depression Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Treatment-Resistant Depression Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Treatment-Resistant Depression Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Neurocrine Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Relmada Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Neuronetics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Treatment-Resistant Depression Market Other Major And Innovative Companies

COMPASS Pathways, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience

38. Global Treatment-Resistant Depression Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Treatment-Resistant Depression Market

40. Treatment-Resistant Depression Market High Potential Countries, Segments and Strategies

40.1 Treatment-Resistant Depression Market In 2030 - Countries Offering Most New Opportunities

40.2 Treatment-Resistant Depression Market In 2030 - Segments Offering Most New Opportunities

40.3 Treatment-Resistant Depression Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Treatment-Resistant Depression Market, Overview Of Key Products - Product Examples
  • Table 2: Global Treatment-Resistant Depression Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Treatment-Resistant Depression Market, Supply Chain Analysis
  • Table 4: Global Treatment-Resistant Depression Market, Major Raw Material Providers
  • Table 5: Global Treatment-Resistant Depression Market, Major Resource Providers
  • Table 6: Global Treatment-Resistant Depression Market, Major Manufacturers (Suppliers)
  • Table 7: Global Treatment-Resistant Depression Market, Major Distributors And Channel Partners
  • Table 8: Global Treatment-Resistant Depression Market, Key Technologies & Future Trends
  • Table 9: Global Treatment-Resistant Depression Market, Major Trends
  • Table 10: Global Treatment-Resistant Depression Market, Major End Users
  • Table 11: Global Treatment-Resistant Depression Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Treatment-Resistant Depression Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Treatment-Resistant Depression Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Treatment-Resistant Depression Market - TAM, US$ Billion, 2025
  • Table 15: Global Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Treatment-Resistant Depression Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Selective Serotonin Reuptake Inhibitors (SSRIs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Monoamine Oxidase Inhibitors (MAOIs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Tricyclic Antidepressants (TCAs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Psychedelics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Treatment-Resistant Depression Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global Treatment-Resistant Depression Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Global Treatment-Resistant Depression Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 98: Global Treatment-Resistant Depression Market - Company Scoring Matrix
  • Table 99: Pfizer Inc. Financial Performance
  • Table 100: Johnson & Johnson Services Inc. Financial Performance
  • Table 101: Neurocrine Biosciences Inc. Financial Performance
  • Table 102: Relmada Therapeutics Inc. Financial Performance
  • Table 103: Neuronetics Inc. Financial Performance
  • Table 104: Global Treatment-Resistant Depression Market, Competitive Benchmarking (In USD Billions)
  • Table 105: Global Treatment-Resistant Depression Market, Competitive Dashboard
  • Table 106: Global Treatment-Resistant Depression Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 107: Global, Treatment-Resistant Depression Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Table 108: Global, Treatment-Resistant Depression Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030
  • Table 109: Global, Treatment-Resistant Depression Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global Treatment-Resistant Depression Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Treatment-Resistant Depression Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Treatment-Resistant Depression Market, Supply Chain Analysis
  • Figure 4: Global Treatment-Resistant Depression Market, Major Raw Material Providers
  • Figure 5: Global Treatment-Resistant Depression Market, Major Resource Providers
  • Figure 6: Global Treatment-Resistant Depression Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Treatment-Resistant Depression Market, Major Distributors And Channel Partners
  • Figure 8: Global Treatment-Resistant Depression Market, Key Technologies & Future Trends
  • Figure 9: Global Treatment-Resistant Depression Market, Major Trends
  • Figure 10: Global Treatment-Resistant Depression Market, Major End Users
  • Figure 11: Global Treatment-Resistant Depression Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Treatment-Resistant Depression Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Treatment-Resistant Depression Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Treatment-Resistant Depression Market - TAM, US$ Billion, 2025
  • Figure 15: Global Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Treatment-Resistant Depression Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Selective Serotonin Reuptake Inhibitors (SSRIs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Monoamine Oxidase Inhibitors (MAOIs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Tricyclic Antidepressants (TCAs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Treatment-Resistant Depression Market, Sub-Segmentation Of Psychedelics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Treatment-Resistant Depression Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global Treatment-Resistant Depression Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Treatment-Resistant Depression Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Treatment-Resistant Depression Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, Treatment-Resistant Depression Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Global Treatment-Resistant Depression Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 98: Global Treatment-Resistant Depression Market - Company Scoring Matrix
  • Figure 99: Pfizer Inc. Financial Performance
  • Figure 100: Johnson & Johnson Services Inc. Financial Performance
  • Figure 101: Neurocrine Biosciences Inc. Financial Performance
  • Figure 102: Relmada Therapeutics Inc. Financial Performance
  • Figure 103: Neuronetics Inc. Financial Performance
  • Figure 104: Global Treatment-Resistant Depression Market, Competitive Benchmarking (In USD Billions)
  • Figure 105: Global Treatment-Resistant Depression Market, Competitive Dashboard
  • Figure 106: Global Treatment-Resistant Depression Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 107: Global, Treatment-Resistant Depression Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Figure 108: Global, Treatment-Resistant Depression Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030
  • Figure 109: Global, Treatment-Resistant Depression Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Read More About CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

Read More About Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Read More About Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Antidepressants Market Report 2026 - Global Outlook – By Product (Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhib...

Major Depressive Disorder Market Report 2026 - Global Outlook – By Treatment (Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments), By Diagnosis (Psychia...

Music Therapy Market Report 2026 - Global Outlook – By Type (Receptive, Active), By Application (Chronic Pain, Substance Abuse Disorder, Neurodevelopment Disorder), By End-User (School, Hospital, Rehabilitation Center) –...

Behavioral Therapy Market Report 2026 - Global Outlook – By Type (Cognitive Behavioral Therapy, Systematic Desensitization, Cognitive Behavioral Play Therapy, Other Types), By Treatment Settings (Hospitals, Community Hea...

Bipolar Disorder Therapeutics Market Report 2026 - Global Outlook – By Drug Class (Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs), By Mechanism (Selective Serotonin Reuptake Inhibitors, Seroton...

Addictions Therapeutics Market Report 2026 - Global Outlook – By Drug Type (Buprenorphine, Naltrexone, Bupropion, Disulfiram, Nicotine Replacement Products, Varenicline, Other Drugs), By Treatment Type (Opioid Addiction ...

Mental Health Apps Market Report 2026 - Global Outlook – By Platform Type (iOS, Android, Other Platform Types), By Application Type (Depression and Anxiety management, Meditation Management, Stress Management, Wellness M...

Addictions Therapeutics Market Report 2026 - Global Outlook – By Drug Type (Buprenorphine, Naltrexone, Bupropion, Disulfiram, Nicotine Replacement Products, Varenicline, Other Drugs), By Treatment Type (Opioid Addiction ...

Frequently Asked Questions

The Treatment-Resistant Depression market was valued at $1.87 billion in 2025, increased to $2 billion in 2026, and is projected to reach $2.59 billion by 2030.

The global Treatment-Resistant Depression market is expected to grow at a CAGR of 6.7% from 2026 to 2035 to reach $2.59 billion by 2035.

Some Key Players in the Treatment-Resistant Depression market Include, Pfizer Inc., Johnson & Johnson Services Inc., Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience .

Major trend in this market includes: Innovative Therapies To Address Unmet Patient Needs In Treatment-Resistant Depression. For further insights on this market. request a sample here

North America was the largest region in the treatment-resistant depression market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the treatment-resistant depression market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us